Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2012/023546, filed Feb 1, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,921,389 | Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase In force · High confidence UsedRemaining | Kyntra Bio, Inc. | In force | High confidence | ||
| US 9,271,970 | Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase In force · High confidence | Kyntra Bio, Inc. | In force | High confidence | ||
| US 9,695,170 | Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase In force · High confidence | Kyntra Bio, Inc. | In force | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.